Low-Dose Calcitriol Decreases Aortic Renin, Blood Pressure, and Atherosclerosis in Apoe-Null Mice

Maya Ish-Shalom; Jessica Sack; Michal Vechoropoulos; Aviv Shaish; Michal Entin-Meer; Yehuda Kamari; Sophia Maysel-Auslender; Gad Keren; Dror Harats; Naftali Stern; Karen Tordjman

doi:10.5551/jat.9621

Original Article

Low-Dose Calcitriol Decreases Aortic Renin, Blood Pressure, and Atherosclerosis in Apoe-Null Mice

Maya Ish-Shalom, Jessica Sack, Michal Vechoropoulos, Aviv Shaish, Michal Entin-Meer, Yehuda Kamari, Sophia Maysel-Auslender, Gad Keren, Dror Harats, Naftali Stern, Karen Tordjman

Author information

Maya Ish-Shalom
The Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv Sourasky Medical Center.
The Sackler Faculty of Medicine, Tel Aviv University.
Jessica Sack
The Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv Sourasky Medical Center.
The Sackler Faculty of Medicine, Tel Aviv University.
Michal Vechoropoulos
The Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv Sourasky Medical Center.
The Sackler Faculty of Medicine, Tel Aviv University.
Aviv Shaish
The Sackler Faculty of Medicine, Tel Aviv University.
The Bert W. Strassburger Lipid Center, Sheba Medical Center.
Michal Entin-Meer
The Sackler Faculty of Medicine, Tel Aviv University.
The Cardiovascular Research Center and Department of Cardiology, Tel Aviv Sourasky Medical Center.
Yehuda Kamari
The Sackler Faculty of Medicine, Tel Aviv University.
The Bert W. Strassburger Lipid Center, Sheba Medical Center.
Sophia Maysel-Auslender
The Sackler Faculty of Medicine, Tel Aviv University.
The Cardiovascular Research Center and Department of Cardiology, Tel Aviv Sourasky Medical Center.
Gad Keren
The Sackler Faculty of Medicine, Tel Aviv University.
The Cardiovascular Research Center and Department of Cardiology, Tel Aviv Sourasky Medical Center.
Dror Harats
The Sackler Faculty of Medicine, Tel Aviv University.
The Bert W. Strassburger Lipid Center, Sheba Medical Center.
Naftali Stern
The Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv Sourasky Medical Center.
The Sackler Faculty of Medicine, Tel Aviv University.
Karen Tordjman
The Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv Sourasky Medical Center.
The Sackler Faculty of Medicine, Tel Aviv University.

Keywords: Atherosclerosis, Blood pressure, Renin, Vitamin D, Renin-angiotensin system, ApoE-null mice, T-regs lymphocytes, Immunomodulation

JOURNAL OPEN ACCESS

2012 Volume 19 Issue 5 Pages 422-434

DOI https://doi.org/10.5551/jat.9621

Browse "Advance Publication"

Details

Abstract

Aims: To determine whether low-dose calcitriol attenuates atherosclerosis in apoE-null mice and, if so, through which predominant mechanism.
Methods: Starting at the age of 6 weeks, mice received intraperitoneal injections of either 0.25 ng/g body weight of calcitriol or the vehicle, every other day for 8 weeks.
Results: Calcitriol treatment resulted in 35% reduction of atherosclerosis at the aortic sinus, and in a significant decrease in blood pressure. These effects were possibly mediated by downregulation of the renin-angiotensin system (RAS), as there was a 64% decrease in the aortic level of renin mRNA. None of the other components of the RAS or the prorenin receptor were affected by treatment. Low-dose calcitriol treatment did not modify the plasma level of monocyte chemoattractant protein-1, interferon γ, interleukin-4 and interleukin-10, which were similar in control and treated mice. Likewise, there was no difference in the percentage of splenic Foxp3⁺ regulatory T cells. Calcitriol treatment resulted in an unfavorable metabolic profile (glucose and lipids), as determined after a limited fast, a difference that disappeared after food was withheld for a longer time.
Conclusions: At a relatively low dosage, calcitriol attenuates the development of atherosclerosis in apoE-null mice, most probably by down regulation of RAS, and not through immunomodulation; however, even at this low dose, calcitriol appears to elevate calcium and to have potentially adverse metabolic effects. Exploring the potential antiatherogenic effects of non-calcemic and safer analogues is therefore warranted.

Corresponding author

Register with J-STAGE for free!